4 completed, 3 terminated, 2 not yet recruiting. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Terminated 3, Not yet recruiting 2 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 2 |
Follow Bone Cancer: new trials by email Literature Review of Bone Cancer trials Research Report on Bone Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) Alectinib - Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | China Medical University Hospital | 10 | 2026-05-15 | 2026-05-11 |
| Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) - Osteosarcoma, Bone Cancer | Phase 1 / Phase 2 | Completed | Shanghai 6th People's Hospital | 10 | 2024-12-03 | 2025-12-29 |
| A Dose Finding Study to Treat Bone Tumor(s) 153-Sm-DOTMP (Samarium-153-DOTMP) - Bone Cancer, Bone Tumor | Phase 1 | Terminated | QSAM Therapeutics, Inc. | 5 | 2022-04-05 | 2026-07-23 |
| Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis combined radiotherapy and MR-HIFU - Bone Metastases, Bone Neoplasm | Phase 1 / Phase 2 | Completed | UMC Utrecht | 10 | 2019-04-11 | 2024-02-07 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. 177Lu-3BP-227 (also called 177Lu-IPN01087) - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 | Terminated | Ipsen | 14 | 2018-05-03 | 2023-12-12 |
| A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) Temozolomide, Vincristine, Ifosfamide - Neoplasms, Solid Tumors | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 4 | 2009-11-11 | 2018-08-27 |
| Vaccine Therapy in Treating Patients With Metastatic Cancer interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51 - Lung Cancer, Adult Soft Tissue Sarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 2000-07-01 | 2024-03-04 | |
| Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors doxorubicin HCl liposome - Childhood Soft Tissue Sarcoma, Childhood Liver Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 1999-07-01 | 2024-03-04 |
Bone Neoplasms (9) · Neoplasms (4) · Osteosarcoma (4) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Genetic Diseases, Inborn (2) · Histiocytoma, Malignant Fibrous (2) · Muscle Neoplasms (2) · Neoplasm Metastasis (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Recurrence (2) · Astrocytoma (1) · Brain Neoplasms (1)
Bone Diseases (9) · Musculoskeletal Diseases (9) · Neoplasms by Site (9) · Neoplasms by Histologic Type (6) · Neoplasms (5) · Neoplasms, Bone Tissue (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3)
Irinotecan (2) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Ifosfamide (1) · Interleukin-2 (1) · Sirolimus (1) · Temozolomide (1) · Vincristine (1) · alectinib (1) · dinutuximab (1) · endostar protein (1) · montanide ISA 51 (1) · robatumumab (1)
National Cancer Institute (NCI) (2) · China Medical University Hospital (1) · Ipsen (1) · Merck Sharp & Dohme LLC (1) · QSAM Therapeutics, Inc. (1) · Shanghai 6th People's Hospital (1) · UMC Utrecht (1) · University Hospital, Strasbourg, France (1)
United States (4) · France (2) · Netherlands (2) · Belgium (1) · China (1) · Switzerland (1) · Taiwan (1)
Barry Sugarman (1) · Elizabeth Lowe (1) · Francesco M. Marincola (1) · Helena M Verkooijen, MD, PhD (1) · Hong-Tao Li, Dr. (1)
2017 (1)